Trials / Not Yet Recruiting
Not Yet RecruitingNCT06927882
Effects of Whole Body Vibration Therapy on Cognitive Function, Balance, and Quality of Life in Older Adults With Mild Cognitive Impairment
Effects of Whole Body Vibration Therapy on Cognitive Function, Balance, and Quality of Life in Older Adults With Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Jouf University · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a double-blind, randomized controlled trial comparing WBV therapy with a placebo intervention and standard care. A total of 150 participants will be recruited and investigated from Prince Mutib Hospital. Participants will be randomly allocated to one of three groups: WBV therapy, placebo (non-vibrating platform), or control (standard care). The study duration will be 12 weeks, with assessments conducted at baseline, post-intervention (12 weeks), and at a 6-month follow-up. Protocol Parameters Summary * Session Frequency: 3 times per week. * Session Duration: 25 minutes per session. * Vibration Frequency: 30 Hz. * Amplitude: 1-2 mm. * Program Duration: 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | WBV Therapy Group | * Frequency: 3 sessions per week for 12 weeks. * Duration: 25 minutes per session. * Vibration Parameters: Participants will undergo whole body vibration therapy at a frequency of 30 Hz, for 25 minutes per session, 3 times a week, with an amplitude of 1-2 mm, over a duration of 12 weeks. |
| OTHER | Placebo Group: | • Participants will stand on a non-vibrating platform and perform similar static and dynamic exercises for the same duration. The platform will mimic the active intervention's noise and display settings to maintain blinding. |
| OTHER | Control | Only assessment at baseline, after 12 weeks and 6 months. |
Timeline
- Start date
- 2025-11-15
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
- First posted
- 2025-04-15
- Last updated
- 2025-11-17
Source: ClinicalTrials.gov record NCT06927882. Inclusion in this directory is not an endorsement.